Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Obstetrics and Gynecology Reports
Published in: Current Obstetrics and Gynecology Reports 1/2014

Open Access 01-03-2014 | Management of Gestational Trophoblastic Diseases (A Cheung, Section Editor)

Management of Chemoresistant and Quiescent Gestational Trophoblastic Disease

Authors: Siew-Fei Ngu, Karen K. L. Chan

Published in: Current Obstetrics and Gynecology Reports | Issue 1/2014

Login to get access

Abstract

Gestational trophoblastic neoplasia (GTN) is highly chemosensitive and has a high cure rate. Since the introduction of chemotherapy, reliable measurement of human chorionic gonadotropin (hCG) levels, and individualised risk-based therapy into the management of GTN, almost all low-risk and more than 80 % of high-risk GTN cases are curable. However, approximately 25 % of high-risk GTN developed resistance to chemotherapy or relapsed after completion of initial therapy, which often necessitate salvage combination chemotherapy. On the other end of the spectrum, a proportion of patients with gestational trophoblastic disease (GTD) have persistently low levels of hCG, without clinical or radiological evidence of disease, a condition called quiescent GTD. Recently, measurement of hyperglycosylated hCG has been proposed for the management of patients with quiescent GTD. Although representing a small proportion of GTD cases, the management of patients with chemoresistant and quiescent GTD often poses challenges to medical practitioners.
Literature
1.
Ngan HY, Kohorn EI, Cole LA, Kurman RJ, Kim SJ, Lurain JR, et al. Trophoblastic disease. Int J Gynaecol Obstet. 2012;119 Suppl 2:S130–6.PubMedCrossRef
2.
• Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2012;12:CD008891. This review aimed to determine the most effective and the least toxic chemotherapy regimen/s for the treatment of resistant or relapsed GTN. No randomized controlled trials were identified.PubMed
3.
Cole LA, Muller CY. Hyperglycosylated hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases. Gynecol Oncol. 2010;116(1):3–9.PubMedCrossRef
4.
Newlands ES. The management of recurrent and drug-resistant gestational trophoblastic neoplasia (GTN). Best Pract Res Clin Obstet Gynaecol. 2003;17(6):905–23.PubMedCrossRef
5.
Lybol C, Sweep FC, Harvey R, Mitchell H, Short D, Thomas CM, et al. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecol Oncol. 2012;125(3):576–9.PubMedCrossRef
6.
Chapman-Davis E, Hoekstra AV, Rademaker AW, Schink JC, Lurain JR. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. Gynecol Oncol. 2012;125(3):572–5.PubMedCrossRef
7.
Powles T, Savage PM, Stebbing J, Short D, Young A, Bower M, et al. A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer. 2007;96(5):732–7.PubMedCentralPubMedCrossRef
8.
Feng F, Xiang Y, Wan X, Zhou Y. Prognosis of patients with relapsed and chemoresistant gestational trophoblastic neoplasia transferred to the Peking Union Medical College Hospital. BJOG. 2010;117(1):47–52.PubMedCrossRef
9.
McNeish IA, Strickland S, Holden L, Rustin GJ, Foskett M, Seckl MJ, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol. 2002;20(7):1838–44.PubMedCrossRef
10.
Sebire NJ, Seckl MJ. Gestational trophoblastic disease: current management of hydatidiform mole. BMJ. 2008;337:a1193.PubMedCrossRef
11.
Lurain JR, Schink JC. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med. 2012;57(5–6):219–24.PubMed
12.
Ngan HY, Tam KF, Lam KW, Chan KK. Methotrexate, bleomycin, and Etoposide in the treatment of gestational trophoblastic neoplasia. Obstet Gynecol. 2006;107(5):1012–7.PubMedCrossRef
13.
Termrungruanglert W, Kudelka AP, Piamsomboon S, Verschraegen CF, Edwards CL, Lifshitz S, et al. Remission of refractory gestational trophoblastic disease with high-dose paclitaxel. Anticancer Drugs. 1996;7(5):503–6.PubMedCrossRef
14.
Pandian Z, Seckl MJ, Smith R, Lees DA. Gestational choriocarcinoma: an unusual presentation with response to gemcitabine and surgery. BJOG. 2004;111(4):382–4.PubMedCrossRef
15.
Bianconi M, Jankilevich G, Otero S, Nassif J, Storino C. Successful salvage of a relapsed high risk gestational trophoblastic neoplasia patient using capecitabine. Gynecol Oncol. 2007;106(1):268–71.PubMedCrossRef
16.
Giacalone PL, Benos P, Donnadio D, Laffargue F. High-dose chemotherapy with autologous bone marrow transplantation for refractory metastatic gestational trophoblastic disease. Gynecol Oncol. 1995;58(3):383–5.PubMedCrossRef
17.
Knox S, Brooks SE, Wong-You-Cheong J, Ioffe O, Meisenberg B, Goldstein DP. Choriocarcinoma and epithelial trophoblastic tumor: successful treatment of relapse with hysterectomy and high-dose chemotherapy with peripheral stem cell support: a case report. Gynecol Oncol. 2002;85(1):204–8.PubMedCrossRef
18.
El-Helw LM, Seckl MJ, Haynes R, Evans LS, Lorigan PC, Long J, et al. High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. Br J Cancer. 2005;93(6):620–1.PubMedCentralPubMedCrossRef
19.
Benigno BB. High-dose chemotherapy with autologous stem cell support as salvage therapy in recurrent gestational trophoblastic disease. Int J Gynecol Cancer. 2013;23(7):1331–3.PubMedCrossRef
20.
Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 2011;204(1):11–8.PubMedCrossRef
21.
Newlands ES, Bower M, Holden L, Short D, Seckl MJ, Rustin GJ, et al. Management of resistant gestational trophoblastic tumors. J Reprod Med. 1998;43(2):111–8.PubMed
22.
Pisal N, North C, Tidy J, Hancock B. Role of hysterectomy in management of gestational trophoblastic disease. Gynecol Oncol. 2002;87(2):190–2.PubMedCrossRef
23.
Lurain JR, Singh DK, Schink JC. Role of surgery in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med. 2006;51(10):773–6.PubMed
24.
Lehman E, Gershenson DM, Burke TW, Levenback C, Silva EG, Morris M. Salvage surgery for chemorefractory gestational trophoblastic disease. J Clin Oncol. 1994;12(12):2737–42.PubMed
25.
Feng F, Xiang Y, Li L, Wan X, Yang X. Clinical parameters predicting therapeutic response to surgical management in patients with chemotherapy-resistant gestational trophoblastic neoplasia. Gynecol Oncol. 2009;113(3):312–5.PubMedCrossRef
26.
Alifrangis C, Wilkinson MJ, Stefanou DC, Virk JS, Anderson J, Seckl MJ. Role of thoracotomy and metastatectomy in gestational trophoblastic neoplasia: a single center experience. J Reprod Med. 2012;57(7–8):350–8.PubMed
27.
Mutch DG, Soper JT, Babcock CJ, Clarke-Pearson DL, Hammond CB. Recurrent gestational trophoblastic disease. Experience of the Southeastern Regional Trophoblastic Disease Center. Cancer. 1990;66(5):978–82.PubMedCrossRef
28.
Cole LA, Khanlian SA, Giddings A, Butler SA, Muller CY, Hammond C, et al. Gestational trophoblastic diseases: 4. Presentation with persistent low positive human chorionic gonadotropin test results. Gynecol Oncol. 2006;102(2):165–72.PubMedCrossRef
29.
Kohorn EI. Persistent low-level "real" human chorionic gonadotropin: a clinical challenge and a therapeutic dilemma. Gynecol Oncol. 2002;85(2):315–20.PubMedCrossRef
30.
Khanlian SA, Smith HO, Cole LA. Persistent low levels of human chorionic gonadotropin: A premalignant gestational trophoblastic disease. Am J Obstet Gynecol. 2003;188(5):1254–9.PubMedCrossRef
31.
Cole LA, Khanlian SA. Inappropriate management of women with persistent low hCG results. J Reprod Med. 2004;49(6):423–32.PubMed
32.
33.
Rotmensch S, Cole LA. False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations. Lancet. 2000;355(9205):712–5.PubMedCrossRef
34.
35.
ACOG. Committee opinion: number 278, November 2002. Avoiding inappropriate clinical decisions based on false-positive human chorionic gonadotropin test results. Obstet Gynecol. 2002;100(5 Pt 1):1057–9.
36.
Cole LA, Khanlian SA, Muller CY. Detection of perimenopause or postmenopause human chorionic gonadotropin: an unnecessary source of alarm. Am J Obstet Gynecol. 2008;198(3):275 e1–7.
37.
Snyder JA, Haymond S, Parvin CA, Gronowski AM, Grenache DG. Diagnostic considerations in the measurement of human chorionic gonadotropin in aging women. Clin Chem. 2005;51(10):1830–5.PubMedCrossRef
38.
39.
Cole LA, Dai D, Butler SA, Leslie KK, Kohorn EI. Gestational trophoblastic diseases: 1. Pathophysiology of hyperglycosylated hCG. Gynecol Oncol. 2006;102(2):145–50.PubMedCrossRef
40.
Guibourdenche J, Handschuh K, Tsatsaris V, Gerbaud P, Leguy MC, Muller F, et al. Hyperglycosylated hCG is a marker of early human trophoblast invasion. J Clin Endocrinol Metab. 2010;95(10):E240–4.PubMedCrossRef
41.
42.
Cole LA, Butler SA, Khanlian SA, Giddings A, Muller CY, Seckl MJ, et al. Gestational trophoblastic diseases: 2. Hyperglycosylated hCG as a reliable marker of active neoplasia. Gynecol Oncol. 2006;102(2):151–9.PubMedCrossRef
43.
Lurain JR. Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010;203(6):531–9.PubMedCrossRef
44.
• Agarwal R, Teoh S, Short D, Harvey R, Savage PM, Seckl MJ. Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study. Lancet. 2012;379(9811):130–5. This study concluded that a surveillance policy seems to be clinically acceptable in patients with low and declining concentrations of hCG 6 months after evacuation of hydatidiform mole.PubMedCentralPubMedCrossRef
45.
Seckl MJ, Savage PM, Hancock BW, Berkowitz RS, Goldstein DP, Lurain JR, et al. Hyperglycosylated hCG in the management of quiescent and chemorefractory gestational trophoblastic diseases. Gynecol Oncol. 2010;117(3):505–6. author reply 6–7.PubMedCrossRef
46.
Cheung AN, Chan KK. Perplexing hCG profile after evacuation of hydatidiform mole. Lancet. 2012;379(9811):98–100.PubMedCrossRef
47.
Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJ. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol. 2000;18(4):854–9.PubMed
48.
Matsui H, Suzuka K, Iitsuka Y, Yamazawa K, Tanaka N, Mitsuhashi A, et al. Salvage combination chemotherapy with 5-fluorouracil and actinomycin D for patients with refractory, high-risk gestational trophoblastic tumors. Cancer. 2002;95(5):1051–4.PubMedCrossRef
49.
Xiang Y, Sun Z, Wan X, Yang X. EMA/EP chemotherapy for chemorefractory gestational trophoblastic tumor. J Reprod Med. 2004;49(6):443–6.PubMed
50.
Wang S, An R, Han X, Zhu K, Xue Y. Combination chemotherapy with 5-fluorouracil, methotrexate and etoposide for patients with high-risk gestational trophoblastic tumors: a report based on our 11-year clinical experiences. Gynecol Oncol. 2006;103(3):1105–8.PubMedCrossRef
51.
Mao Y, Wan X, Lv W, Xie X. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen. Int J Gynaecol Obstet. 2007;98(1):44–7.PubMedCrossRef
52.
Wan X, Xiang Y, Yang X, Wu Y, Liu N, Chen L, et al. Efficacy of the FAEV regimen in the treatment of high-risk, drug-resistant gestational trophoblastic tumor. J Reprod Med. 2007;52(10):941–4.PubMed
53.
Lu WG, Ye F, Shen YM, Fu YF, Chen HZ, Wan XY, et al. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients. Int J Gynecol Cancer. 2008;18(2):357–62.PubMedCrossRef
54.
Wang J, Short D, Sebire NJ, Lindsay I, Newlands ES, Schmid P, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Ann Oncol. 2008;19(9):1578–83.PubMedCrossRef
55.
Zhao Y, Zhang W, Duan W. Management of gestational trophoblastic neoplasia with 5-fluorouracil and actinomycin D in northern China. J Reprod Med. 2009;54(2):88–94.PubMed
56.
Feng F, Xiang Y, Wan X, Geng S, Wang T. Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia. Ann Oncol. 2011;22(7):1588–94.PubMedCrossRef
57.
Manopunya M, Suprasert P. Resistant gestational trophoblastic neoplasia patients treated with 5-fluorouracil plus actinomycin D. Asian Pac J Cancer Prev. 2012;13(1):387–90.PubMedCrossRef
Metadata
Title
Management of Chemoresistant and Quiescent Gestational Trophoblastic Disease
Authors
Siew-Fei Ngu
Karen K. L. Chan
Publication date
01-03-2014
Publisher
Springer US
Published in
Current Obstetrics and Gynecology Reports / Issue 1/2014
Electronic ISSN: 2161-3303
DOI
https://doi.org/10.1007/s13669-013-0071-6

Other articles of this Issue 1/2014

Current Obstetrics and Gynecology Reports 1/2014 Go to the issue

Molecular Pathogenesis of Gynecologic Cancer (H Katabuchi and H Tashiro, Section Editors)

The Relationship Between Estrogen and Genes in the Molecular Pathogenesis of Endometrial Carcinoma

Management of Gestational Trophoblastic Diseases (A Cheung, Section Editor)

Clinical Epidemiology of Gestational Trophoblastic Disease

Management of Gestational Trophoblastic Diseases (A Cheung, Section Editor)

Negative Pregnancy Test in Patients with Trophoblastic Diseases

Management of Gestational Trophoblastic Diseases (A Cheung, Section Editor)

Management Options of Gestational Trophoblastic Disease

Management of Gestational Trophoblastic Diseases (A Cheung, Section Editor)

The hCG Group: the Key Molecules in Human Evolution, Human Life, and Human Death

Molecular Pathogenesis of Gynecologic Cancer (H Katabuchi and H Tashiro, Section Editors)

Pathogenesis of the Endometriosis-Related Ovarian Neoplasms